Comparison of eradication rates of moxifloxacin–rifabutin triple therapy and bismuth quadruple therapy as second‐line regimens in patients with peptic ulcers

Lee, Chang Min; Kim, Seong Je; Hah, Se In; Kwak, Ji Yoon; Choi, Jung Woo; Cho, Hyun Chin; Ha, Chang Yoon; Lee, Ok Jae; Jung, Woon Tae

doi:10.1002/hsr2.780

Cited by 1 publication

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study by Chang Ming Lee had 323 participants divided into two cohorts [ 23 ]. The moxifloxacin-rifabutin triple therapy (MRT) treatment regimen was administered to 71 individuals who were unsuccessful with the first-line clarithromycin regimen (Cohort 1), while 252 patients with the same condition received the BQ treatment regimen (Cohort 2).…”

Section: Reviewmentioning

confidence: 99%

See 1 more Smart Citation

Effectiveness of Rifabutin-Based Regimens in Treating Helicobacter pylori Infections

Gugnani,

Abhishek,

Agarwal

et al. 2023

Cureus

View full text Add to dashboard Cite

Helicobacter pylori has been reported as a health problem worldwide, affecting a sizable portion of people. Peptic ulcers, gastric cancer, and various extra gastric conditions are associated with this bacterium. The rampant overprescribing of antibiotics has led to the emergence of H. pylori strains resistant to multiple antibiotics, causing a decline in the effectiveness of current treatments. Recently, there has been growing interest in researching alternative treatment options for H. pylori infections that do not respond to initial therapy. Rifabutin, a rifamycin derivative initially designed for tuberculosis treatment and preventing Mycobacterium avium complex infection, has gained attention as a potential rescue medication. It has shown efficacy against H. pylori and the potential to eradicate the bacterium when combined with other antibiotics. This systematic review article focuses on using rifabutin-based regimens as a treatment option after initial treatments have failed. The authors screened literature published in the last five years, between 2017 and 2022, across various search engines and closely examined relevant studies following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria. The search covered a variety of electronic databases and focused on H. pylori gastritis, rifabutin-based treatment plans, and in vivo investigations in healthy individuals. The comprehensive review provides convincing evidence that rifabutin-based regimens are effective rescue treatments for H. pylori infections. Multiple studies in various areas consistently demonstrated high eradication rates, ranging from 70% to 90%, when rifabutin-containing regimens were used. The analysis found that only a tiny percentage of H. pylori strains (1%) were resistant to rifabutin therapy, further supporting the viability of Rifabutin as an alternative when other antibiotics failed to eradicate H. pylori. The cost of Rifabutin is a significant factor that may limit its accessibility, particularly in resource-constrained settings where H. pylori infection is common. Moreover, the potential side effects of Rifabutin, such as hematological problems, rashes, and digestive issues, need to be considered. However, these side effects are typically manageable and can be reduced by combining Rifabutin with other antibiotics. In conclusion, this systematic review provides evidence supporting the effectiveness of regimens derived from Rifabutin in eliminating H. pylori infections after initial therapy failure. Due to the observation that Rifabutin effectively eradicates resistant H. pylori infections, it can be considered a suitable choice for rescue therapy. Rifabutin-containing regimens should be reserved as fourth- or later-line therapy options, considering economic factors, the risk of microbial resistance, potential side effects, and the availability of alternative medications. Future research should focus on optimizing rifabutin-based regimens and investigating combination therapies that have better H....

show abstract

Section: Reviewmentioning

confidence: 99%

“…This retrospective research was carried out by Chang Ming Lee et al [ 23 ]. Due to limited patient compliance and a convoluted dose strategy, finding a suitable third-line treatment when BQ therapy fails is difficult.…”

Section: Reviewmentioning

confidence: 99%